Assignee
MEDAREX INC
US·87 granted patents·22 pending applications·11,322 citations·filing 1994–2013
Top patents by PatentIndex Score
109 records- 0199US9102725B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2013·Granted Aug 11, 2015·120 cites·31 claims
- 0299US8383796B2Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2011·Granted Feb 26, 2013·355 cites·31 claims
- 0399US8017114B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2009·Granted Sep 13, 2011·199 cites·33 claims
- 0499US8008449B2Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeuticsMEDAREX INC·Filed 2006·Granted Aug 30, 2011·2.2k cites·23 claims
- 0599US7943743B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2006·Granted May 17, 2011·1.5k cites·26 claims
- 0699US7605238B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2001·Granted Oct 20, 2009·353 cites·32 claims
- 0799US7501552B2Transgenic non-human animals for producing chimeric antibodiesMEDAREX INC·Filed 2004·Granted Mar 10, 2009·182 cites·3 claims
- 0899US6984720B1Human CTLA-4 antibodiesMEDAREX INC·Filed 2000·Granted Jan 10, 2006·897 cites·14 claims
- 0999US5922845ATherapeutic multispecific compounds comprised of anti-Fcα receptor antibodiesMEDAREX INC·Filed 1996·Granted Jul 13, 1999·448 cites·24 claims
- 1098US7910798B2Transgenic animals expressing chimeric antibodies for use in preparing human antibodiesMEDAREX INC·Filed 2007·Granted Mar 22, 2011·130 cites·5 claims
- 1198US7517903B2Cytotoxic compounds and conjugatesMEDAREX INC·Filed 2005·Granted Apr 14, 2009·161 cites·19 claims
- 1298US7507420B2Peptidyl prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2005·Granted Mar 24, 2009·148 cites·32 claims
- 1398US7498302B2Disulfide prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2005·Granted Mar 3, 2009·123 cites·32 claims
- 1498US7129261B2Cytotoxic agentsMEDAREX INC·Filed 2002·Granted Oct 31, 2006·282 cites·24 claims
- 1598US7087600B2Peptidyl prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2002·Granted Aug 8, 2006·259 cites·32 claims
- 1698US6989452B2Disulfide prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2002·Granted Jan 24, 2006·284 cites·21 claims
- 1798US5837243ATherapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1996·Granted Nov 17, 1998·545 cites·18 claims
- 1897US8034959B2Methods of treating cancer with an antibody-drug conjugateMEDAREX INC·Filed 2009·Granted Oct 11, 2011·37 cites·19 claims
- 1997US7714016B2Cytotoxic compounds and conjugates with cleavable substratesMEDAREX INC·Filed 2006·Granted May 11, 2010·45 cites·21 claims
- 2097US7662381B2Interferon alpha receptor 1 antibodies and their usesMEDAREX INC·Filed 2005·Granted Feb 16, 2010·47 cites·20 claims
- 2197US6270765B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1998·Granted Aug 7, 2001·215 cites·9 claims
- 2296US7977465B2Peptidyl prodrugs and linkers and stabilizers useful thereforMEDAREX INC·Filed 2009·Granted Jul 12, 2011·14 cites·21 claims
- 2396US7968586B2Cytotoxic compounds and conjugatesMEDAREX INC·Filed 2006·Granted Jun 28, 2011·39 cites·18 claims
- 2496US7691962B2Chemical linkers and conjugates thereofMEDAREX INC·Filed 2005·Granted Apr 6, 2010·200 cites·47 claims
- 2596US7456264B2Human monoclonal antibodies against Bacillus anthracis protective antigenMEDAREX INC·Filed 2004·Granted Nov 25, 2008·88 cites·32 claims
- 2696US7452535B2Methods of treatment using CTLA-4 antibodiesMEDAREX INC·Filed 2003·Granted Nov 18, 2008·70 cites·18 claims
- 2796US6303755B1Therapeutic multispecific compounds comprised of anti-FCA receptor antibodiesMEDAREX INC·Filed 1999·Granted Oct 16, 2001·116 cites·17 claims
- 2896US6063116AModulation of cell proliferation and wound healingMEDAREX INC·Filed 1995·Granted May 16, 2000·259 cites·15 claims
- 2995US7875278B2Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residuesMEDAREX INC·Filed 2006·Granted Jan 25, 2011·56 cites·14 claims
- 3095US7847105B2Methods and compounds for preparing CC-1065 analogsMEDAREX INC·Filed 2006·Granted Dec 7, 2010·33 cites·15 claims
- 3195US7476513B2Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigenMEDAREX INC·Filed 2005·Granted Jan 13, 2009·29 cites·16 claims
- 3295US7387776B2Human monoclonal antibodies against CD30MEDAREX INC·Filed 2003·Granted Jun 17, 2008·70 cites·15 claims
- 3395US7135287B1Human antibodiesMEDAREX INC·Filed 2000·Granted Nov 14, 2006·62 cites·12 claims
- 3495US5833985ABispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicityMEDAREX INC·Filed 1995·Granted Nov 10, 1998·163 cites·8 claims
- 3594US8383118B2Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1MEDAREX INC·Filed 2006·Granted Feb 26, 2013·24 cites·11 claims
- 3694US7465446B2Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of diseaseMEDAREX INC·Filed 2004·Granted Dec 16, 2008·52 cites·19 claims
- 3794US7329507B2Prodrug compounds with isoleucineMEDAREX INC·Filed 2006·Granted Feb 12, 2008·27 cites·5 claims
- 3894US7115573B2Prodrug compounds with an isoleucineMEDAREX INC·Filed 2001·Granted Oct 3, 2006·61 cites·41 claims
- 3994US6962981B1Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigenMEDAREX INC·Filed 2000·Granted Nov 8, 2005·52 cites·20 claims
- 4093US7744875B2Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of diseaseMEDAREX INC·Filed 2008·Granted Jun 29, 2010·16 cites·10 claims
- 4193US7214663B2Tripeptide prodrug compoundsMEDAREX INC·Filed 2001·Granted May 8, 2007·52 cites·26 claims
- 4293US6897034B2CD10-activated prodrug compoundsMEDAREX INC·Filed 2002·Granted May 24, 2005·52 cites·10 claims
- 4393US6410690B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1995·Granted Jun 25, 2002·91 cites·17 claims
- 4493US6365161B1Therapeutic compounds comprised of anti-FC receptor binding agentsMEDAREX INC·Filed 1999·Granted Apr 2, 2002·113 cites·20 claims
- 4592US6682928B2Cells expressing anti-Fc receptor binding componentsMEDAREX INC·Filed 1998·Granted Jan 27, 2004·89 cites·24 claims
- 4691US8802632B2Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereofMEDAREX INC·Filed 2013·Granted Aug 12, 2014·12 cites·13 claims
- 4791US7425541B2Enzyme-cleavable prodrug compoundsMEDAREX INC·Filed 2001·Granted Sep 16, 2008·37 cites·23 claims
- 4891US7192582B2Human monoclonal antibodies to FC alpha receptor (CD89)MEDAREX INC·Filed 2002·Granted Mar 20, 2007·52 cites·16 claims
- 4990US8034787B2Enzyme-cleavable prodrug compoundsMEDAREX INC·Filed 2008·Granted Oct 11, 2011·8 cites·17 claims
- 5090US7576258B2Transgenic transchromosomal rodents for making human antibodiesMEDAREX INC·Filed 2005·Granted Aug 18, 2009·7 cites·10 claims
Showing the top 50 of 109 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MEDAREX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →